Avelumab in Patients With Metastatic Colorectal Cancer

Abstract Background Metastatic colorectal cancer (mCRC) is incurable, and median overall survival is less than 2½ years. Although monoclonal antibodies that block PD-1/PD-L1 interactions are active in microsatellite unstable/mismatch repair deficient tumors, a growing dataset shows that most patient...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2023-09, Vol.28 (9), p.823-e804
Hauptverfasser:	Redman, Jason M, O’Sullivan Coyne, Geraldine, Reed, Clay T, Madan, Ravi A, Strauss, Julius, Steinberg, Seth J, Marté, Jennifer, Cordes, Lisa, Heery, Christopher, Gulley, James L
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical Trial Results Colorectal cancer Drug therapy Metastasis Patient outcomes
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!